Concepedia

Hiromi Tabuchi

HT

Statistics

Publications

8

Citations

166

H-Index

8

Active since

2016

Affiliations

Astellas Pharma (Japan)(Current)

University of Toyama

Shiga University of Medical Science

Hiromi Tabuchi is an author at Astellas Pharma (Japan) specializing in medicine, liver physiology, and health sciences.

Top concepts

Publications per year

2016–2020

8

Publications

8

Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study

Ichiro Nakamura, Hiroshi Maegawa, Kazuyuki Tobe et al. · Expert Opinion on Pharmacotherapy · 2017 · 35 citations · Full text

Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real‐World Clinical Setting: A<scp>J</scp>apanese Post‐Marketing Study

Yumiko Nozawa, Daisuke Kato, Hiromi Tabuchi et al. · LUTS Lower Urinary Tract Symptoms · 2016 · 28 citations · Full text

Baseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice

Hiroshi Maegawa, Kazuyuki Tobe, Hiromi Tabuchi et al. · Expert Opinion on Pharmacotherapy · 2016 · 24 citations

Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: a subgroup analysis of the STELLA-LONG TERM study (3-month interim results)

Hiromi Tabuchi, Hiroshi Maegawa, Kazuyuki Tobe et al. · Endocrine Journal · 2018 · 21 citations · Full text

, , +15

Safety and effectiveness of mirabegron in patients with overactive bladder aged ≥75 years: Analysis of a Japanese post‐marketing study

Masaki Yoshida, Yumiko Nozawa, Daisuke Kato et al. · LUTS Lower Urinary Tract Symptoms · 2017 · 19 citations · Full text

1–5 of 8